iPS – Barrier Free Japan

by Michael Gillan Peckitt June 5, 2025 0

Japan Starts Final-Stage Trial for iPS Drug for Alzheimer’s

A Japanese team said on Tuesday 3rd June that it has started a final-stage clinical trial to administer to patients with familial Alzheimer’s disease a drug discovered through induced pluripotent stem, or iPS, cells. This is the first final-stage trial conducted in the field of iPS drug discovery, which uses iPS cells to discover new efficacies of new and existing drugs, according to the team. The team includes members of Kyoto University’s Center for iPS Cell Research and Application, or CiRA, and Towa Pharmaceutical Co., which makes and sells generic drugs.

by Michael Gillan Peckitt April 16, 2025 0

iPS Japan Medical

Kyoto Hospital Succeeds in iPS Sheet Transplant to Diabetic

Kyoto University Hospital has succeeded in transplanting pancreatic cell sheets made from induced pluripotent stem, or iPS, cells into a diabetic patient, achieving the first clinical application of such sheets in Japan. Announcing the results Monday, the hospital said that the patient in her 40s has already been discharged with a favorable prognosis. The hospital observed her for one month after the surgery and confirmed that there was no safety problem.

by Michael Gillan Peckitt March 24, 2025 0

Disability Expo 2025 Health iPS Japan

“Osaka Healthcare Pavilion” Unveiled to Press

A preview ceremony was held Sunday for the “Osaka Healthcare Pavilion” to be run by the prefecture and city of Osaka at the 2025 World Exposition, which begins next month in the western Japan city.   Inside the pavilion, a myocardial cell sheet using induced pluripotent stem, or iPS, cell technology and an experience-based area where avatars are generated based on visitors’ health data were shown to the press.

by Michael Gillan Peckitt June 15, 2023 0

Genetics iPS Japan Transplantation

Japan Group Starts iPS Cell Supplies with Less Rejection Risk

When a transplant is performed, rejection occurs if the type of human leukocyte antigens, or HLA, of the donor does not conform with that of the recipient.

Using genome-editing technology, the foundation altered genes related to immune cells to create the iPS cells with lower rejection risk.

by Michael Gillan Peckitt January 14, 2022 0

Disability Genetics iPS Japan

World’s 1st iPS Therapy for Spinal Cord Injuries Starts in Japan

Japan’s Keio University said Friday it has started a clinical research to transplant neural progenitor cells derived from induced pluripotent stem, or iPS, cells into patients with spinal cord injuries, the first such attempt in the world.